Maxim Group Has Lowered Expectations for Oncolytics Biotech (NASDAQ:ONCY) Stock Price

Oncolytics Biotech (NASDAQ:ONCY) had its target price lowered by Maxim Group from $5.00 to $3.00 in a research note issued to investors on Monday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research report on Monday. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Royal Bank of Canada lowered their price objective on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Three analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Price Performance

NASDAQ ONCY opened at $0.63 on Monday. The firm’s fifty day moving average price is $0.77 and its 200 day moving average price is $0.92. The company has a market capitalization of $53.87 million, a price-to-earnings ratio of -2.33 and a beta of 1.18. Oncolytics Biotech has a 12 month low of $0.58 and a 12 month high of $1.53.

Institutional Trading of Oncolytics Biotech

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after acquiring an additional 24,997 shares during the period. National Bank of Canada FI lifted its stake in shares of Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after acquiring an additional 42,955 shares during the period. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter worth $90,000. Vantage Point Financial LLC acquired a new stake in shares of Oncolytics Biotech in the 4th quarter worth $27,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after acquiring an additional 26,069 shares during the period. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.